Metastatic uveal melanoma

International Ophthalmology Clinics

Volumn 46, Issue 1, 2006, Pages 133-149

  Kivelä, Tero ^a   Eskelin, Sebastian ^a   Kujala, Emma ^a  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; DACARBAZINE; FOTEMUSTINE; GEMCITABINE; INTERLEUKIN 2; LOMUSTINE; RECOMBINANT ALPHA2 INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERFERON; RECOMBINANT INTERLEUKIN 2; TREOSULFAN; TUMOR VACCINE; VINCRISTINE;

AGE DISTRIBUTION; ALOPECIA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SCREENING; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CORRELATION ANALYSIS; DISEASE COURSE; DOSE CALCULATION; ECHOGRAPHY; HUMAN; INCIDENCE; KARNOFSKY PERFORMANCE STATUS; LEUKOPENIA; LIVER FUNCTION TEST; LIVER METASTASIS; LIVER RESECTION; LUNG FIBROSIS; METASTASIS; NEUROTOXICITY; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; TREATMENT OUTCOME; UVEA MELANOMA; DIFFERENTIAL DIAGNOSIS; HEALTH; MELANOMA; PATHOLOGY; SURVIVAL RATE; UVEA TUMOR;

DIAGNOSIS, DIFFERENTIAL; HUMANS; INCIDENCE; MELANOMA; PROGNOSIS; SURVIVAL RATE; UVEAL NEOPLASMS; WORLD HEALTH;

EID: 33644877482     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.iio.0000195861.71558.13     Document Type: Review

References (59)

1. Sobin LH, Wittekind Ch. TNM Classification of Malignant Tumours. New York: Wiley-Liss; 2002.
2. Kujala E, Mäkitie T, Kivelä T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44:4651-4659.
3. Aoyama T, Mastrangelo MJ, Berd D, et al. Protracted survival after resection of metastatic uveal melanoma. Cancer. 2000;89:1561-1568.
4. Eskelin S, Pyrhonen S, Summanen P, et al. Screening for metastatic malignant melanoma of the uvea revisited. Cancer. 1999;85:1151-1159.
5. The Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119:670-676.
6. Lorigan JG, Wallace S, Mavligit GM. The prevalence and location of metastases from ocular melanoma: imaging study in 110 patients. AJR Am J Roentgenol. 1991;157:1279-1281.
7. Patel JK, Didolkar MS, Pickren JW, et al. Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg. 1978;135:807-810.
8. Albert DM, Ryan LM, Borden EC. Metastatic ocular and cutaneous melanoma: a comparison of patient characteristics and prognosis. Arch Ophthalmol. 1996;114:107-108.
9. Tojo D, Wenig BL, Resnick KI. Incidence of cervical metastasis from uveal melanoma: implications for treatment. Head Neck. 1995;17:137-139.
10. Dithmar S, Diaz CE, Grossniklaus HE. Intraocular melanoma spread to regional lymph nodes: report of two cases. Retina. 2000;20:76-79.
11. Bergman L, Seregard S, Nilsson B, et al. Uveal melanoma survival in Sweden from 1960 to 1998. Invest Ophthalmol Vis Sci. 2003;44:3282-3287.
12. Collins VP, Loeffler RK, Tivey H. Observations on growth rates of human tumors. AJR Am J Roentgenol. 1956;76:988-1000.
13. Eskelin S, Pyrhönen S, Summanen P, et al. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107:1443-1449.
14. Manschot WA, van Peperzeel HA. Choroidal melanoma. Enucleation or observation? A new approach. Arch Ophthalmol. 1980;98:71-77.
15. Singh AD. Uveal melanoma: implications of tumor doubling time [Letter]. Ophthalmology. 2001;108:829-831.
16. The Collaborative Ocular Melanoma Study Group. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma I: characteristics of patients enrolled and not enrolled. COMS report no. 9. Am J Ophthalmol. 1998;125:767-778.
17. Diener-West M, Earle JD, Fine SL, et al. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, II: characteristics of patients enrolled and not enrolled. COMS report no. 17. Arch Ophthalmol. 2001;119:951-965.
18. Gombos DS, Van Quill KR, Uusitalo M, et al. Geographic disparities in diagnostic screening for metastatic uveal melanoma. Ophthalmology. 2004;111:2254-2258.
19. Eskelin S, Pyrhönen S, Hahka-Kemppinen M, et al. A prognostic model and staging for metastatic uveal melanoma. Cancer. 2003;97:465-475.
20. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Screening for metastasis from choroidal melanoma: the Collaborative Ocular Melanoma Study Group Report 23. J Clin Oncol. 2004;22:2438-2444.
21. Kaiserman I, Amer R, Pe'er J. Liver function tests in metastatic uveal melanoma. Am J Ophthalmol. 2004;137:236-243.
22. Felberg NT, Shields JA, Maguire J, et al. Gamma-glutamyl transpeptidase in the prognosis of patients with uveal malignant melanoma. Am J Ophthalmol. 1983;95:467-473.
23. Leyvraz S, Spataro V, Bauer J, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol. 1997;15:2589-2595.
24. Char DH. Metastatic choroidal melanoma. Am J Ophthalmol. 1978;86:76-80.
25. Bedikian AY, Kantarjian H, Young SE, et al. Prognosis in metastatic choroidal melanoma. South Med J. 1981;74:574-577.
26. Donoso LA, Berd D, Augsburger JJ, et al. Metastatic uveal melanoma. Pretherapy serum liver enzyme and liver scan abnormalities. Arch Ophthalmol. 1985;103:796-798.
27. Schaller UC, Bosserhoff AK, Neubauer AS, et al. Melanoma inhibitory activity: a novel serum marker for uveal melanoma. Melanoma Res. 2002;12:593-599.
28. Missotten GS, Tang NE, Korse CM, et al. Prognostic value of S-100-beta serum concentration in patients with uveal melanoma. Arch Ophthalmol. 2003;121:1117-1119.
29. Donoso LA, Nagy RM, Brockman RJ, et al. Metastatic uveal melanoma. Hepatic cell-surface enzymes, isoenzymes, and serum sialic acid levels in early metastatic disease. Arch Ophthalmol. 1983;101:791-794.
30. Bedikian AY, Legha SS, Mavligit G, et al. Treatment of uveal melanoma metastatic to the liver: a review of the MD Anderson Cancer Center experience and prognostic factors. Cancer. 1995;76:1665-1670.
31. Eskelin S, Kivelä T. Imaging to detect metastases from malignant uveal melanoma [Letter]. Arch Ophthalmol. 2002;120:676.
32. Ferry AP, Font RL. Carcinoma metastatic to the eye and orbit. I. A clinicopathologic study of 227 cases. Arch Ophthalmol. 1974;92:276-286.
33. Hicks C, Foss AJ, Hungerford JL. Predictive power of screening tests for metastasis in uveal melanoma. Eye. 1998;12:945-948.
34. Gragoudas ES, Egan KM, Seddon JM, et al. Survival of patients with metastases from uveal melanoma. Ophthalmology. 1991;98:383-389.
35. Kivelä T, Suciu S, Hansson J, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer. 2003;39:1115-1120.
36. Salmon RJ, Levy C, Plancher C, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol. 1998;24:127-130.
37. Foss AJ, Alexander RA, Jefferies LW, et al. Microvessel count predicts survival in uveal melanoma. Cancer Res. 1996;56:2900-2903.
38. Mäkitie T, Summanen P, Tarkkanen A, et al. Microvascular density in predicting survival of patients with choroidal and ciliary body melanoma. Invest Ophthalmol Vis Sci. 1999;40:2471-2480.
39. Chen X, Maniotis AJ, Majumdar D, et al. Uveal melanoma cell staining for CD34 and assessment of tumor vascularity. Invest Ophthalmol Vis Sci. 2002;43:2533-2539.
40. Toivonen P, Mäkitie T, Kujala E, et al. Microcirculation and tumor-infiltrating macrophages in choroidal and ciliary body melanoma and corresponding metastases. Invest Ophthalmol Vis Sci. 2004;45:1-6.
41. Pyrhönen S, Hahka-Kemppinen M, Muhonen T, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer. 2002;95:2366-2372.
42. Terheyden P, Bröcker EB, Becker JC. Clinical evaluation of in vitro chemosensitivity testing: the example of uveal melanoma. J Cancer Res Clin Oncol. 2004;130:395-399.
43. Cantore M, Fiorentini G, Aitini E, et al. Intra-arterial hepatic carboplatin-based chemotherapy for ocular melanoma metastatic to the liver. Report of a phase II study. Tumori. 1994;80:37-39.
44. Becker JC, Terheyden P, Kämpgen E, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer. 2002;87:840-845.
45. Egerer G, Lehnert T, Max R, et al. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol. 2001;6:25-28.
46. Pföhler C, Cree IA, Ugurel S, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs. 2003;14:337-340.
47. Albert DM, Niffenegger AS, Willson JK. Treatment of metastatic uveal melanoma: review and recommendations. Surv Ophthalmol. 1992;36:429-438.
48. Pyrhönen S. The treatment of metastatic uveal melanoma. Eur J Cancer. 1998;34(suppl 3):S27-S30.
49. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res. 1999;9:575-581.
50. Singh AD, Borden EC. Metastatic uveal melanoma. Ophthalmol Clin North Am. 2005;18:143-150.
51. Hahka-Kemppinen M, Muhonen T, Kangas L, et al. Chemosensitivity of human melanoma metastases in mouse subrenal capsule assay - can it predict tumour response to combined cytostatic plus interferon therapy in metastatic melanoma? Melanoma Res. 1996;6:215-221.
52. Nathan FE, Berd D, Sato T, et al. BOLD + interferon in the treatment of metastatic uveal melanoma: first report of active systemic therapy. J Exp Clin Cancer Res. 1997;16:201-208.
53. Neale MH, Myatt N, Cree IA, et al. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside. Br J Cancer. 1999;79:1487-1493.
54. Neale MH, Myatt NE, Khoury GG, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res. 2001;11:601-609.
55. Keilholz U, Schuster R, Schmittel A, et al. A clinical phase I trial of gemcitabine and treosulfan in uveal melanoma and other solid tumours. Eur J Cancer. 2004;40:2047-2052.
56. Elias D, Cavalcanti de Albuquerque A, Eggenspieler P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients. J Am Coll Surg. 1998;187:487-493.
57. Fournier GA, Albert DM, Arrigg CA, et al. Resection of solitary metastasis. Approach to palliative treatment of hepatic involvement with choroidal melanoma. Arch Ophthalmol. 1984;102:80-82.
58. Gunduz K, Shields JA, Shields CL, et al. Surgical removal of solitary hepatic metastasis from choroidal melanoma. Am J Ophthalmol. 1998;125:407-409.
59. Spitler LE, Wong P, Sagebiel R. Combined immunotherapy of malignant melanoma. Unusual survival following cerebral metastasis. Arch Dermatol. 1978;114:1501-1504.